HYPERTHERMIA FOR GLIOBLASTOMA
COMBINING HEAT WITH RADIATION AND TEMOZOLOMIDE

Glioblastoma is the most common and most aggressive primary brain tumour in adults. Despite two decades of intensive research, the standard Stupp protocol remains the backbone of treatment — and median survival has improved only modestly. This is the gap that thermal therapies are attempting to address.

“For glioblastoma, every meaningful gain in survival has come from adding modalities to the standard protocol — not from replacing them. Hyperthermia fits that pattern.”

• The Stupp Protocol Has Plateaued

  Maximal safe resection followed by concurrent radiation + temozolomide (the Stupp protocol) remains the global standard since 2005. Median overall survival is approximately 14–16 months in unselected populations, with 5-year survival under 10%. Tumour recurrence within the original treatment field is nearly universal.

• Treatment Resistance Is Multi-Layered

  Glioblastoma cells deploy aggressive DNA repair (driven by MGMT methylation status), inhabit hypoxic tumour zones resistant to radiation, and shelter behind the blood-brain barrier that limits drug penetration. Hyperthermia mechanistically targets each of these failure modes — the rationale for adding heat to standard therapy.

Heating tumours inside the skull is fundamentally harder than treating tumours in the pelvis, chest, or extremities. Engineering and biology both push back — which explains why GBM hyperthermia has developed differently from regional hyperthermia in other cancers.

• The Skull Reflects and Distorts External Energy

  Bone strongly reflects and absorbs radiofrequency energy, making external phased-array hyperthermia (the standard pelvic technology) unreliable in the cranium. Heat distribution is uneven and unpredictable, often producing hotspots in the skull rather than the tumour.

• Normal Brain Tissue Has Low Thermal Tolerance

  Neurons are highly heat-sensitive. Temperatures above 43°C cause permanent neurological damage in healthy brain tissue, while the therapeutic range for tumour killing typically requires 40–45°C. This narrow safety margin is the central engineering constraint.

• Temperature Monitoring Is Invasive

  Unlike pelvic tumours where probes can sit in body cavities, brain temperature monitoring requires invasive intracranial probes or MR thermometry — both technically demanding and not universally available.

• Tumour Heterogeneity Is Extreme in GBM

  Glioblastoma tumours are highly infiltrative with poorly defined margins. Achieving uniform therapeutic heating across this irregular volume — without scorching nearby brain — requires precision delivery rather than broad regional heating.

• These Constraints Have Shaped GBM Hyperthermia Toward Local Delivery

  Rather than external regional heating, GBM hyperthermia has evolved toward local, image-guided delivery: interstitial catheters, magnetic nanoparticles injected directly into tumour tissue, and MR-guided focal heating. The technologies in clinical use today reflect these biological constraints.

Several thermal delivery methods have been studied or used clinically in GBM. Each has different requirements, evidence levels, and regulatory status.

The strongest direct evidence for thermal therapy in GBM comes from interstitial hyperthermia and magnetic nanoparticle approaches. Both add meaningful survival improvement when combined with standard radiation or re-irradiation.

NanoTherm (developed by MagForce AG) is the most clinically advanced GBM hyperthermia approach in routine use. It received CE marking in 2010 for recurrent glioblastoma and is offered at specialist centres in Germany. Here is how it works in practice.

• Step 1: Direct Tumour Injection of Iron Oxide Nanoparticles

  Under stereotactic navigation, biocompatible iron oxide nanoparticles in aqueous suspension are injected directly into the tumour through small burr holes. The nanoparticles distribute through the tumour and adjacent infiltrative margins, where they bind preferentially to malignant tissue.

• Step 2: External Alternating Magnetic Field Heating

  The patient sits inside a magnetic field applicator (the NanoActivator device). An alternating magnetic field at 100 kHz causes the iron oxide nanoparticles to oscillate, generating heat at the tumour site. Surrounding healthy brain tissue contains no nanoparticles and is not heated significantly.

• Step 3: Repeated Sessions with Re-Irradiation

  Six magnetic field activation sessions are typically delivered over 2–4 weeks, each lasting approximately 60 minutes. Sessions are paired with low-dose re-irradiation in patients with recurrent GBM, since this is the population for which the approach is approved.

• Imaging and Monitoring

  The iron nanoparticles are visible on CT imaging, allowing precise verification of placement and continued monitoring. MRI is limited during treatment because the magnetic nanoparticles produce artifacts; CT and clinical assessment are used during the treatment course.

GBM hyperthermia access is limited and requires specialist centres. Patients with recurrent disease or those seeking thermal options alongside standard therapy follow a structured evaluation pathway.

1. 1

   Submit Imaging, Pathology, and Treatment History

   Recent contrast-enhanced MRI, neuropathology with IDH status and MGMT methylation, original surgical reports, and complete record of prior radiation and temozolomide are required for evaluation.

2. 2

   Neuro-Oncology Multi-Disciplinary Review

   A neurosurgeon, neuro-oncologist, radiation oncologist, and hyperthermia specialist review the imaging, prior treatment, and current disease status to determine whether hyperthermia is technically and clinically appropriate.

3. 3

   Treatment Planning

   For NanoTherm, stereotactic injection planning is performed using imaging fusion. For interstitial approaches, catheter trajectories are planned. For combination with re-irradiation, dose constraints based on prior cumulative radiation are recalculated.

4. 4

   Procedure and Treatment Sessions

   For NanoTherm, nanoparticle injection is a brief stereotactic procedure under local anaesthesia, followed by 6 magnetic activation sessions over 2–4 weeks. Other modalities have different procedural requirements.

5. 5

   Response Monitoring and Follow-Up

   Response is assessed by clinical evaluation and follow-up imaging (CT for NanoTherm patients due to MRI artifacts; MRI for other modalities). Long-term follow-up monitors for further progression and continued systemic therapy.

Explore the full hyperthermia knowledge base and related cancer treatment pages.

Frequently Asked Questions

Common questions from patients, caregivers, and clinicians about hyperthermia for glioblastoma.